Delhi | 25°C (windy)

Urgent Alert: iRobot Investors Face Critical Deadline in Class Action Lawsuit – Don't Miss Your Chance to Act!

  • Nishadil
  • September 08, 2025
  • 0 Comments
  • 2 minutes read
  • 4 Views
Urgent Alert: iRobot Investors Face Critical Deadline in Class Action Lawsuit – Don't Miss Your Chance to Act!

Attention, iRobot Corporation (NASDAQ: IRBT) shareholders! A significant development demands your immediate attention. The distinguished national securities law firm, Faruqi & Faruqi, LLP, has issued a crucial reminder regarding the pending class action lawsuit filed on behalf of investors who purchased iRobot common stock between August 24, 2022, and January 26, 2024, inclusive (the “Class Period”).

This legal action alleges a breach of federal securities laws, and the deadline for investors to seek appointment as lead plaintiff is fast approaching: April 15, 2025.

The lawsuit, captioned Scharf v. iRobot Corporation et al., No. 1:24-cv-00806, is currently pending in the U.S.

District Court for the District of Delaware. It centers on serious allegations that iRobot, along with certain of its senior officers, made materially false and misleading statements to the investing public and/or omitted crucial information. These alleged misrepresentations revolved around the company’s merger agreement with Amazon.com, Inc.

and its overall business prospects.

Specifically, the complaint alleges that throughout the Class Period, iRobot and its leadership failed to disclose that the completion of the Amazon acquisition was highly unlikely to receive antitrust approval in the European Union. Furthermore, it is claimed that the European Commission was set to issue an unfavorable ruling regarding the merger.

Investors were allegedly left unaware that Amazon and iRobot possessed, or were expected to acquire, substantial market power that would raise significant competitive concerns in the E.U. This alleged lack of transparency meant that the deal, heavily touted as a major growth driver, was in peril.

The truth, according to the lawsuit, began to emerge on January 26, 2024.

On this date, multiple news outlets reported that the Amazon-iRobot merger was expected to be blocked by European Union antitrust regulators. This news sent shockwaves through the market, causing iRobot's stock price to plummet. Following these reports, the company officially announced that it had mutually agreed to terminate the merger agreement with Amazon, citing the failure to obtain necessary regulatory approval from the European Commission.

In the wake of this revelation, iRobot's stock price experienced a staggering decline of $9.13 per share, or 8.76%, closing at $11.80 per share on January 29, 2024. This significant drop inflicted substantial losses upon unsuspecting investors.

Faruqi & Faruqi, LLP emphasizes that if you purchased iRobot stock during the specified Class Period and suffered losses exceeding $100,000, you have a critical opportunity to play a pivotal role in this litigation.

You do not need to take any action to remain an absent member of the class. However, by seeking appointment as lead plaintiff, you can have a direct impact on the direction and outcome of the lawsuit. A lead plaintiff acts on behalf of all class members, selecting and overseeing legal counsel, and making key decisions regarding the litigation strategy.

The deadline to file your motion to be appointed lead plaintiff is April 15, 2025.

Faruqi & Faruqi, LLP, a firm renowned for its track record of securing substantial recoveries for investors, urges affected shareholders to contact them for a confidential, no-cost consultation. You can reach Partner Josh Wilson at jwilson@faruqilaw.com or via telephone at (877) 247-4292. Alternatively, you can contact Partner James V.

Bashian at jbashian@faruqilaw.com or (877) 247-4292. Don't let this opportunity pass to seek justice and potentially recover your investment losses. Your proactive participation can make a difference.

.

Disclaimer: This article was generated in part using artificial intelligence and may contain errors or omissions. The content is provided for informational purposes only and does not constitute professional advice. We makes no representations or warranties regarding its accuracy, completeness, or reliability. Readers are advised to verify the information independently before relying on